Do you want to read an article? Please log in or register.
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study
Lung Cancer
Related content
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
RECOMMENDED
Lung Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
RECOMMENDED
Lung Cancer
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A
doi: 10.1016/j.cllc.2025.12.007
Lung Cancer
Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data
Clin Lung Cancer
Hettinger GCN, Long Q, Parikh RB
doi: 10.1016/j.cllc.2025.09.010
Lung Cancer
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L
Clin Lung Cancer
Kataoka S, Shukuya T, Ohtsu H, Miyawaki T, Fujimoto D, Hayashi H, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Otsubo K, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Yamamoto N, Okamoto I, Takahashi K
doi: 10.1016/j.cllc.2025.12.002
Lung Cancer
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors
Lung Cancer
Mudumba R, Liu X, Jin S, Davis IJ, Baid D, Romley JA, Nieva JJ
doi: 10.1016/j.lungcan.2026.109451
RECOMMENDED
Lung Cancer
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Gemelli M, Sala L, Morabito A, Sforza V, Cortellini A, La Cava G, Bertolini F, Guaitoli G, Carnio S, Novello S, Leonetti A, Tiseo M, Mazzoni F, Cosso F, Macerelli M, Membrino A, Metro G, Chiari R, Genova C, Berardi R, Tassistro E, Antolini L, Cortinovis DL
doi: 10.1016/j.ejca.2026.116579
Lung Cancer
Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study
J Clin Med
Acar O, Agaoglu AB, Sahbazlar M, Ekinci F, Erdogan AP
doi: 10.3390/jcm14207287
Lung Cancer
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
Eur J Cancer
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A
doi: 10.1016/j.ejca.2026.116902